GLIMEPIRIDE + METFORMIN — Competitive Intelligence Brief

GLIMEPIRIDE + METFORMIN (GLIMEPIRIDE + METFORMIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea + biguanide combination. Area: Diabetes.

marketed Sulfonylurea + biguanide combination ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I Diabetes Small molecule

Target snapshot

GLIMEPIRIDE + METFORMIN (GLIMEPIRIDE + METFORMIN) — Sanofi. Glimepiride stimulates pancreatic insulin secretion while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GLIMEPIRIDE + METFORMIN TARGET	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Glibenclamide and Metformin	Glibenclamide and Metformin	Takeda	marketed	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I
Glibenclamide + Metformin	Glibenclamide + Metformin	University of Zambia	phase 3	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial complex I and AMP-activated protein kinase
Glimepiride and Metformin	Glimepiride and Metformin	Takeda	phase 3	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Glimepiride); Complex I of mitochondrial electron transport chain (Metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea + biguanide combination class)

1. Sanofi · 1 drug in this class